Navigation Links
Adiponectin shows potential in blocking obesity-related carcinogenesis
Date:10/19/2010

A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), and could offer a promising therapy for the disease.

Obesity is on the rise and is associated with increased risk and progression of a number of cancers including colon, prostate, breast, and liver cancers. The World Health Organization declared obesity one of the greatest public health challenges of the 21st century and projects that by 2015, more than 700 million adults will be obese. In the U.S., the Centers for Disease Control and Prevention (CDC) estimates roughly 72.5 million adults are considered obesehaving a body mass index (BMI) greater than 30.

Obese populations have higher circulating levels of leptin, the protein hormone that controls appetite, but lower concentrations of adiponectin which regulates glucose levels and the breakdown of fatty acids. Understanding the these hormones play a role in obesity-related cancers and the vast number of individuals who are at risk, Neeraj K. Saxena, Ph.D. and colleagues investigated the protective effect of adiponectin and its impact on leptin in HCC.

"Our study presents important clinical implications since HCC has the highest increased risk associated with obesity compared to other cancers such as prostate, kidney, colon, and stomach," commented Dr. Saxena. Using human cell-lines, mice models of HCC, and tissue microarray researchers determined the antagonistic role of adiponectin on the cancer-causing actions of leptin.

The authors found that adiponectin treatment inhibited leptin-induced proliferation, invasion, and migration of HCC cells. Treatment with adiponectin also slowed leptin-induced HCC tumor growth in vivo. Further analysis showed that leptin expression correlated positively with HCC proliferation and nonalcoholic steatohepatitis (NASH). Adiponectin expression had an inverse correlation with tumor size, and a direct correlation to disease-free survival in human HCC tumor samples.

"Taken together our results suggest an attractive molecular strategy employing adiponectin analogues for potential therapy of metastatic HCC," concluded Dr. Saxena. "With the prevalence of obesity in the U.S., our study could significantly improve overall survival for a vast number of obese liver cancer patients by using adiponectin to inhibit growth, invasion, and migration of HCC cells."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. First blinded study of venous insufficiency prevalence in MS shows promising results
2. People with anxiety disorder less able to regulate response to negative emotions, study shows
3. Poll Shows Eroding Support for Health Reform
4. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
5. Compound shows promise against intractable heart failure
6. Drama or reality TV: Do medical shows depict proper first aid for seizures?
7. TV Shows Often Botch Proper Seizure Responses
8. UQ research shows canecutters disease on the rise among travelers
9. Brain Scan Shows What Beauty is Worth
10. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
11. New research shows emotional impact of low sexual desire and associated distress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... protecting their workers from extreme heat at their worksites. Employers with workers ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: